Our cell therapy manufacturing automation partner Oribiotech has signed a 10-year partnership, worth up to US$120 million, with an undisclosed commercial stage biopharmaceutical company. Under it, Oribiotech’s IRO® platform will be integrated into the manufacture of a cell therapy that is already approved and on the market.

Why this matters to AdAlta: IRO® is the manufacturing platform we chose in April 2026, when AdAlta, Oribiotech and Australian contract manufacturer Cell Therapies Pty Ltd signed a Memorandum of Understanding to deploy it for our cellular immunotherapy pipeline. A commercial stage biopharmaceutical company is exactly the profile of the eventual buyer or commercialisation partner for AdAlta’s products – and one of them has now chosen the same platform.

Switching manufacturing after a product is approved is the highest bar in our industry. Because every dose is made individually from living cells, the process is effectively part of the product, and any company that changes it must satisfy regulators that the therapy still performs the same way in patients. Committing a decade and up to US$120 million to do exactly that is a far more powerful endorsement of IRO® than any pilot study.

IRO® is designed to deliver 10 to 50 times more output from the same footprint, 30-50% lower manufacturing costs and more consistent product quality – the things that decide whether a cell therapy that works in a trial can be supplied profitably to large numbers of patients.

EW-001, our lead CAR-T cell therapy, was licensed before the Oribiotech collaboration and already has its own low cost, rapid and scalable manufacturing process, so it will not be made on IRO®. For the products that follow, IRO® compatibility is now a design priority – meaning our future pipeline can be offered to large biopharma on a manufacturing platform they have already validated and put into commercial use.